Cas9 Stable Cell Line - BV2

The Cas9 Stable Cell Line - BV2 is a genetically engineered BV2 mouse microglia cell line that stably expresses CRISPR-associated protein 9 (Cas9). The BV2 cell line originates from primary microglia of C57/BL6 mice, is immortalized through retroviral transformation, and exhibits key microglia characteristics, including phagocytic activity, cytokine secretion, and morphological plasticity. Cas9 integration is achieved via lentiviral transduction or plasmid transfection, followed by antibiotic selection to ensure stable genome integration. This cell line constitutively expresses Cas9 under the control of a strong promoter, thus maintaining nuclease activity without repeated transfection. The cell line has been rigorously validated to maintain microglia markers such as Iba1 and CD11b and exhibits strong proliferative capacity.

This Cas9 Stable Cell Line - BV2 revolutionizes research in neuroimmunology and neurodegenerative diseases. It enables high-throughput CRISPR screening to identify genes regulating microglia activation (M1/M2 polarization), phagocytosis, and inflammatory responses to stimuli such as LPS or β-amyloid. Researchers have used this cell line to construct Parkinson''s and Alzheimer''s disease models by knocking out target genes such as TREM2 or NLRP3, elucidating the roles of these target genes in neuroinflammation and neuronal death. In drug development, this cell line can facilitate rapid target validation (e.g., testing small-molecule inhibitors targeting microglia-specific pathways) and toxicity assessment. Furthermore, the Cas9-BV2 cell line simplifies modeling of similar in vivo diseases in preclinical studies, reduces dependence on primary cells, and ensures genetic consistency.